Pathophysiology of COVID-19 and its potential therapeutics

Sarfaraz Alam Khan, Nazeem Ishrat Siddiqui


A series of acute and atypical serious respiratory illnesses were reported in December 2019 from Wuhan, a city of China. It spread to other places and became a global pandemic involving more than 200 countries of the world. Soon, it was discovered that this atypical respiratory illness was caused by a novel corona virus. It was named as the severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and the disease caused by it as corona virus disease-19 (COVID-19). Since COVID-19 is a new viral disease, world is still struggling to find out a permanent remedy to control this serious health problem. It seems prudent to study or have a look on the pathophysiology of SARS CoV-2 in the light of available research. Further, a review on pathophysiology may give an insight on the potential therapeutic options. Being a new virus and having potential to cause significant morbidity and mortality in short span of time various approved drugs are being repurposed for the treatment of COVID-19.


COVID-19, Pathophysiology, Therapeutics

Full Text:



Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Paret T, Emery S et al. A Novel coronavirus Associated with severe acute respiratory syndrome, N Engl J Med. 2003;348:1953-66.

Zhang J, Litvinova M , Wang W, Wang Y, Deng X, Chen X et al. Evolving epidemiology and transmission Dynamics of coronavirus disease 2019 outside Hubei provience , China: a descriptive and modelling study. Lancet Infect Dis. 2020;20(7):793-802.

Anthony SJ, Johnson CK, Greig DJ, Kramer S, Che X, Wells H, et al. Global Partners in coronavirus diversity.Virus Evol 2017;3(1)vex012.

Johnson CK, Hitchens PL, Evans TS, Goldstein T,Thomas K, Clements A et al. Spillover and pandemic properties of zoonotic viruses with high host plasticity. Sci Rep. 2015;5:14830.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Yet al. Early Transmission dynamics in Wuhan, China, of Novel Coronavirus-infected Pneumonia. N Engl J Med. 2020;382:1199-207.

Dorsten C, Gunther S, Preiser W, Van der Werf S, Brodt HR, Becker S et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome , N Engl J Med. 2003;348(20):1967.

Zaki AM, Boheemen SV, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirusfrom a men with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20.

Wu F, Jhao S, Yu B, Chen YM, Wang W, Song ZGet al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579 (7798): 265-9.

Huang C, Wang Y, Li X, Ren L, Jhao J, Hu Y at al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu Jet al. Radiological findings from 81 patients with COVID -19 pneumonia in Wuhan, China a descriptive study. Lancet Infect Dis. 2020;20:425-34.

Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, Goettsche Met al. Genomic characterization of severe acute respiratory syndrome – related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol. 2010;84(21): 11336-49.

Drexler JF, CormanVM, Drosten C. Ecology evolution and classification of bat coronavirus in the aftermath of SARS. Antivir Res 2014;101:45-56.

Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1-23.

Tortorici MA, Veesler D. Structural insights into coronavirus entry. Adv Virus Res 2019; 105: 93-116.

15. Tortorici MA, Walls AC, Lang Y, Wang C, Li. Z, Koerhuis D et al. Structural basis for human coronavirus attachment to sialic acid receptors. Nat Struct Mol Biol. 2019;26(6):481-9.

Walls AC, Xiong X, Park YJ, Tortorici MA, Snijder J, Quispe J et al. Unexpected receptor functional Mimicry Elueidates Activation of coronavirus fusion. Cell. 2019;176(5):1026-39.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, Goor HV. Tissue distribution of ACE2 Protien, the functional receptors for SARScoronavirus, A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-7.

Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithilia: role of ciliated cell in viral spread in the conducting airways of the lungs. J Virol 2005;79(24):15511-24.

Sungnak WH, Becavin C. Berg M. HCA Lung Biological Network. SARS-cov-2 Entry Genes Are Most Highly Expressed in Nasal Goblet and Ciliated Cells within Human Airways. arXiv. 2020:2003.06122.

Xu H, Zhong I, Deng J, Peng J, Dan H, Zeng X et al. High exoression of ACE2 receptor of 2019-nCOV on epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):9.

Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z et al. The use of anti-in-flammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.

Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications of SARS. Nat Rev Immunol. 2005;5(12):917-27.

Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccine: Lessons Learned from SARS and MERS epidemic, Asian Pac J Allergy Immunol. 2020;38(1):1-9.

Wit ED, Doremalen NV, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-34.

Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753-66.

Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK et al.Antibody responses to SARS-COV-2 in patients with COVID-19. Nat Med. 2020;26(6):845-8.

Murrell S, Wu SC, Butler M. Review of dengue virus and the development of vaccine. Biotechnol Adv. 2011;29(2):239-47.

Liu L, Wei Q, Lin Q, Fang J, Wang H , Kwok H et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507-13.

Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanism to Potential Therapeutic Tools. Virol Sin 2020;35(3):266-71.

Garvin MR, Alvarez C, Miller JI, Prates TE, Walker AM, Amos BK et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife 2020;9:e59177.

Is a Bradykinin Storm Brewing in COVID-19? Available at: Accessed on15th September 2020.

The Lancet Haematology. COVID-19 coagulopathy: an evolving story. Lancet Haematol 2020;7(6):e425.

Mogielnicki A, Kramkowski K, Hermanowicz JM, Leszczynska A, Przyborowski K, Buczko W. Angiotensin- (1-9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis. Journal of the Renin-Angiotensin-Aldosterone System. 2014;15:13–21.

Kanasaki K. N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: an update and translational aspects. Journal of Diabetes Investigation 2020;11:516–26.

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A et al. Current pharmacological treatments for COVID-19: What’s next? Br J Pharmacol 2020;177(21):4813-24.

National Institutes of Health (2020). NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins. Available at: news-events/news-releases/nih-clinical-trial-shows-remdesivir-acceleratesrecovery-advanced-covid-19. Accessed om 30 July 2020.

FurutaY, Gowen BB, Takahashi K,Shiraki K, Smee DF, and Barnard D. L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–54.

Clinicaltrials.Gov (2020l). Clinical Study to Evaluate the Performance And Safety of Favipiravir in COVID-19. Available at: NCT04336904. Accessed on 08 April 2020.

Westover JB, Mathis A, Taylor R, Wandersee L, Bailey K W, Sefing E J et al. Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antiviral Res. 2018;156:38–45.

Clinicaltrials.Gov (2020bp). A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19. Available at: Accessed on 15 April 2020.

Barragan P, Podzamczer D. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment. Expert Opin Pharmacother. 2008;9:2363–75.

Clinicaltrials. Gov (2020ak). Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection. Available at: Accessed on 10 February 2020.

Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X et al. (2020). First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients. Med Rxiv. 2020.2003.2022.20034041.

Campbell WC, Fisher MH, Stapley EO, Albers-Schönberg G, Jacob TA, Ivermectin. A potent new antiparasitic agent. Science 1983;221:823–28.

Clinicaltrials. Gov (2020bv). Trial to Promote Recovery from COVID-19 with Ivermectin or Endocrine Therapy (RECOVER). Available at: https:// (Accessed on 05 May 2020.

Hemady RK, Sinibaldi VJ andEisenberger MA. Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Am J Ophthalmol. 1996;121:291–6.

Chictr. Org.Cn (2020d). A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19). Available at: Accessed on 21 February 2020.

Dunn CJ and Barradell LB. Azithromycin. Drugs 1996;51:483–505.

Mohammad FS, Karmakar V, and Irfan. Z. Hydroxychloroquine and azithromycin combination could be lethal to covid-19 patients. Farmacia 2020;68(3):384–9.

Sargiacomo C, Sotgia F, and Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging. 2020;12:6511–17.

Clinicaltrials.Gov (2020y). DYNAMIC Study (DoxycYcliNeAMbulatoIre COVID19) (DYNAMIC). Available at: NCT04371952. Accessed on 07 May 2020.

Claman HN Corticosteroids and Lymphoid Cells. New Engl J Med. 1972;287:388–97.

Russell CD, Millar JE, and Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473– 5.

Chun J and Hartung (H P.). Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33:91–101.

Clinicaltrials.Gov (2020al). Fingolimod in COVID-19. Available at: https:// Accessed on 21 February 2020.

Shannon E, Noveck R, Sandoval F, and Kamath B. Thalidomide suppressed IL-1beta while enhancing TNF-alpha and IL-10, when cells in whole blood were stimulated with lipopolysaccharide. Immunopharmacol Immunotoxicol 2008;30:447–57.

Clinicaltrials.Gov (2020ac). The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia. Available at: Accessed on 21 February 2020.

Rozman B. Clinical Pharmacokinetics of Leflunomide. Clin Pharmacokinet 2002;41:421–30.

Clinicaltrials.Gov (2020ar). Leflunomide in Mild COVID-19 Patients. Available at: Accessed on 11 May 2020.

Clinicaltrials.Gov (2020m). Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) (COVID-19). Available at: NCT04322682. Accessed on 24 April 2020.

Clinicaltrials.Gov (2020as). LIBERATE Trial in COVID-19 (LIBERATE). Available at: Accessed on 01 May 2020.

Clinicaltrials.Gov (2020ae). Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection (ENACOVID). Available at: Accessed on 14 April 2020.

Clinicaltrials.Gov (2020ap). Jaktinib Dihydrochloride Monohydrate in Idiopathic Pulmonary Fibrosis. Available at: NCT04312594. Accessed on 30 April 2020.

Clinicaltrials.Gov (2020ax). Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Patients with COVID-19 Associated Cytokine Storm (RUXCOVID) (RUXCOVID). Available at: Accessed on 07 May 2020.

Clinicaltrials.Gov (2020f). Baricitinib in Symptomatic Patients Infected by COVID19: an Open-label, Pilot Study. Available at: NCT04320277 Accessed on 22 April 2020.

Clinicaltrials.Gov (2020bs). TOFAcitinib in SARS-CoV2 Pneumonia. Available at: (Accessed on 02 April 2020.

Ying W, QianY, and Kun Z. Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic. Res Soc Administrative Pharm 2020; 1520:30325–9.

Chictr.Org.Cn (2020c). Efficacy and safety of tozumab combined with adamumab (Qletli) in severe and critical patients with novel coronavirus pneumonia (COVID-19). Available at: 50693. Accessed on 15 March 2020.

Röth A, Rottinghaus ST, Hill A, Bachman ES, Kim JS, Schrezenmeier H et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018;2: 2176–85.

Clinicaltrials.Gov (2020ad). Efficacy and Safety Study of IV Ravulizumab in Patients with COVID-19 Severe Pneumonia. Available at: https://clinicaltrials. gov/ct2/show/NCT04369469. Accessed on 30 April 2020.

Clinicaltrials.Gov (2020bo). Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19). Available at: Accessed on 01 May 2020.

Le, RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23:943–7.

Clinicaltrials.Gov (2020br). Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19) (CORON-ACT). Available at: Accessed on 28 April 2020.

Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2016;44(2):275–81.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020;2:e393–400.

Abassi ZA, Skorecki K, Heyman SN, Kinaneh S, Armaly Z. Covid-19 infection and mortality - A physiologist’s perspective enlightening clinical features and plausible interventional strategies. Am J Phys Lung Cell Mol Physiol. 2020;318(5):1020-L1022.

Clinicaltrials.Gov (2020bf). Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP). Available at: /NCT02735707 Accessed on 16 April 2020.

Meng J, Xiao G, Zhang J, He X, Ou M , Jing B. et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020;9(1):757-760.

Rojas M, Rodrıguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.

May, JM, and Harrison, FE. Role of vitamin C in the function of the vascular endothelium. Antioxid. Redox Signal. 2013;19: 2068–83.

Wilson JX. Evaluation of vitamin C for adjuvant sepsis therapy. Antioxid Redox Signal. 2013;19: 2129–40.

Clinicaltrials.Gov (2020c). Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation (AVoCaDO). Available at: Accessed on 22 April 2020.

Clinicaltrials.Gov (2020aq). The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations (LEAD COVID-19). Available at: Accessed on 06 May 2020.

Clinicaltrials.Gov (2020x). COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in Highrisk COVID-19 Patients (CoVitTrial). Available at: https:// Accessed on 06 May 2020.